Login to Your Account

Lpath Inc.'s stock plunged 79.5 percent on word of the lead compound's phase II blowup, but "there exists some true assets that can be built upon," spokeswoman Pam Lord told BioWorld Today, and the company is restructuring to conserve money.

Following extensive talks with the FDA and European regulators, Intercept Pharmaceuticals Inc. has nailed down plans for a rigorous pivotal phase III study testing obeticholic acid, its lead candidate, in about 2,500 patients with NASH.

To develop safer combination therapies is still critical, and "we think that's particularly true in breast cancer," Oncothyreon Inc.
More IN THE CLINIC Headlines

Cast Your Vote

Has biotech’s bubble burst?: